Hochschulschrift
Docetaxel in the management of PSA progression following primary androgen deprivation for prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Köln, Univ., Diss., 2009
- Schlagwort
-
Krebs
Onkologie
- Urheber
- URN
-
urn:nbn:de:hbz:38m-0000000822
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:53 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Hochschulschrift
Beteiligte
Ähnliche Objekte (12)
Docetaxel in the management of PSA progression following primary androgen deprivation for prostate cancer
TRIM25 controls the Androgen Receptor and PSA/KLK3 levels in Prostate Cancer
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Detection rate of 68Ga-PSMA Ligand PET/CT in patients with recurrent prostate cancer and androgen deprivation therapy
Androgen receptor expression in the clinically localized prostate cancer
Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer
The role of physical activity and structured exercise for physical fitness and immune function in men on androgen deprivation therapy for prostate cancer
Die prognostische Relevanz eines initialen PSA-Anstiegs unter Chemotherapie mit Docetaxel bei hormonrefraktärem Prostatakarzinom
Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis
Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis
Androgen receptor‐mediated transcriptional repression targets cell plasticity in prostate cancer
Androgen receptor deregulation drives bromodomain-mediated chromatin alterations in prostate cancer
Docetaxel in the management of PSA progression following primary androgen deprivation for prostate cancer
TRIM25 controls the Androgen Receptor and PSA/KLK3 levels in Prostate Cancer
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Detection rate of 68Ga-PSMA Ligand PET/CT in patients with recurrent prostate cancer and androgen deprivation therapy
Androgen receptor expression in the clinically localized prostate cancer
Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer
The role of physical activity and structured exercise for physical fitness and immune function in men on androgen deprivation therapy for prostate cancer
Die prognostische Relevanz eines initialen PSA-Anstiegs unter Chemotherapie mit Docetaxel bei hormonrefraktärem Prostatakarzinom
Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis
Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis
Androgen receptor‐mediated transcriptional repression targets cell plasticity in prostate cancer
Androgen receptor deregulation drives bromodomain-mediated chromatin alterations in prostate cancer
Docetaxel in the management of PSA progression following primary androgen deprivation for prostate cancer
TRIM25 controls the Androgen Receptor and PSA/KLK3 levels in Prostate Cancer
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Detection rate of 68Ga-PSMA Ligand PET/CT in patients with recurrent prostate cancer and androgen deprivation therapy
Androgen receptor expression in the clinically localized prostate cancer
Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer
The role of physical activity and structured exercise for physical fitness and immune function in men on androgen deprivation therapy for prostate cancer
Die prognostische Relevanz eines initialen PSA-Anstiegs unter Chemotherapie mit Docetaxel bei hormonrefraktärem Prostatakarzinom
Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis
Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis
Androgen receptor‐mediated transcriptional repression targets cell plasticity in prostate cancer